SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-209727
Filing Date
2023-08-11
Accepted
2023-08-11 07:01:59
Documents
12
Period of Report
2023-08-07
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d530241d8k.htm   iXBRL 8-K 23317
  Complete submission text file 0001193125-23-209727.txt   148060

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20230807.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230807_lab.xml EX-101.LAB 18757
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230807_pre.xml EX-101.PRE 11706
6 EXTRACTED XBRL INSTANCE DOCUMENT d530241d8k_htm.xml XML 3533
Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231161482
SIC: 2834 Pharmaceutical Preparations